BIOCRYST PHARMACEUTICALS, INC. Payments of Stock Issuance Costs
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Payments of Stock Issuance Costs of -$17.81 million for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-11-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2012-11-08
- BIOCRYST PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2012-09-30 was -$2.47M, a 11871.43% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2011-09-30 was $21.00K.
- BIOCRYST PHARMACEUTICALS, INC. payments of stock issuance costs for the quarter ending 2010-09-30 was $0.00.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month |
|---|---|---|---|
| 2012-09-30 | -$2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$17.81M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | -$15.34M 10-Q · filed 2012-08-08 | ||
| 2011-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $94.00K 10-Q · filed 2012-11-08 | |
| 2011-06-30 | $73.00K 10-Q · filed 2012-08-08 | ||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $84.00K 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $84.00K 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |